<scp>Long‐term</scp> efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled <scp>52‐week</scp> outcomes from the <scp>DEPICT</scp> ‐1 and ‐2 studies

Abstract

Over 52 weeks, dapagliflozin provided glycaemic and weight benefits, with no increased frequency of severe hypoglycaemia compared with placebo. More DKA events were reported with dapagliflozin than placebo, highlighting the importance of appropriate patient selection, education and risk-mitigation strategies.